Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2014

View Archived Issues

Celsion completes acquisition of EGEN

Merck KGaA to begin phase I trial of MSB-0010841 in patients with psoriasis

Orexo reports phase III data on Zubsolv for induction of buprenorphine maintenance therapy

Scripps Research Institute and T23 sign license for CD22 siglec oncoimmunological platform

Inovio's INO-3112 enters phase I/IIa trial in cervical cancer

Ultra-long-acting LAPS-insulin well tolerated and active in type 1 and 2 diabetes

Phase II results reported for indisulam with idarubicin and cytarabine in myeloid malignancies

Results of phase I trial: pevonedistat in combination with azacitidine for AML

Dose-escalation study of mPEG-r-crisantaspase, a new PEGylated asparaginase

Phase I and expansion cohort results presented for a yeast-based therapeutic cancer vaccine

EDO-S101, a novel candidate for the treatment of multiple myeloma

Verona Pharma's VRP-700 misses endpoint in chronic cough trial

Bayer HealthCare and Dimension Therapeutics to develop novel gene therapy for hemophilia A

Living Cell Technologies resumes trial of encapsulated cell therapy in Parkinson's disease

XenoPort begins phase II trial of XP-23829 in patients with psoriasis

Genocea reports topline phase I data for universal pneumococcus vaccine candidate

EMA's COMP adopts positive opinion on marizomib in multiple myeloma

Akorn sells subsidiary to Valeant Pharmaceuticals

Trevena reports phase I results for TRV-734 in acute and chronic pain

Hangzhou Zylox Pharma discloses new rapamycin analogues

Boehringer Ingelheim decides not to pursue hepatitis C drug development

NovoMedix patents novel treatments for cancer and fibrosis

Kyowa Hakko Kirin patent reports new CCR10 receptor antagonists

Allergan board of directors rejects exchange offer from Valeant Pharmaceuticals

Scientists at Temple University prepare and test novel 5-HT2B antagonists

Sunovion Pharmaceuticals reports development of PDE10A inhibitors

Roche files IND to begin phase II study of Erivedge in IPF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...